Literature DB >> 28707317

Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients.

Y Teramoto1,2, U Keim1,3, A Gesierich4, G Schuler5, E Fiedler6, T Tüting7, C Ulrich8, U Wollina9, J C Hassel10, R Gutzmer11, S Goerdt12, C Zouboulis13, U Leiter1, T K Eigentler1, C Garbe1.   

Abstract

BACKGROUND: Acral lentiginous melanoma (ALM) is one of the four major subtypes in cutaneous melanoma (CM). Although ALM has a poorer prognosis than other CM subtypes, the prognostic factors associated with ALM have only been verified in small-sized cohorts because of the low incidence of ALM worldwide.
OBJECTIVES: To investigate the clinical characteristics of ALM and to evaluate their prognostic values based on a large dataset from the Central Malignant Melanoma Registry (CMMR) of the German Dermatologic Society.
METHODS: The Kaplan-Meier method was used to estimate the potential influence of clinical and histological parameters on ALM disease-specific survival (DSS) curves, which were compared using the log-rank test. A Cox proportional hazards model was used to identify independent prognostic factors for DSS.
RESULTS: In total, 2050 patients with ALM were identified from 58 949 patients with CM recorded by the CMMR with follow-up data. In multivariate analyses, age (P = 0·006), ulceration (P = 0·013), tumour thickness (P < 0·001) and tumour spread (P < 0·001) turned out to be significant prognostic factors for DSS in ALM whereas sex, nevus association and level of invasion were not independent factors.
CONCLUSIONS: ALM has the same prognostic factors as other subtypes of melanoma. Unfavourable prognosis probably derives from the delay in diagnosis in comparison with other melanoma subtypes.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2017        PMID: 28707317     DOI: 10.1111/bjd.15803

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  20 in total

Review 1.  Emerging strategies to treat rare and intractable subtypes of melanoma.

Authors:  Gretchen M Alicea; Vito W Rebecca
Journal:  Pigment Cell Melanoma Res       Date:  2020-04-24       Impact factor: 4.693

2.  Clinical and genetic analysis of melanomas arising in acral sites.

Authors:  Anne Zaremba; Rajmohan Murali; Philipp Jansen; Inga Möller; Antje Sucker; Annette Paschen; Lisa Zimmer; Elisabeth Livingstone; Titus J Brinker; Eva Hadaschik; Cindy Franklin; Alexander Roesch; Selma Ugurel; Dirk Schadendorf; Klaus G Griewank; Ioana Cosgarea
Journal:  Eur J Cancer       Date:  2019-08-14       Impact factor: 9.162

3.  Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers.

Authors:  Clio Dessinioti; Niki Dimou; Alan C Geller; Aravella Stergiopoulou; Serigne Lo; Ulrike Keim; Jeffrey E Gershenwald; Lauren E Haydu; Simone Ribero; Pietro Quaglino; Susana Puig; Josep Malvehy; Lidija Kandolf-Sekulovic; Tatjana Radevic; Roland Kaufmann; Laura Meister; Eduardo Nagore; Victor Traves; Grigorios G Champsas; Mihaela Plaka; Brigitte Dreno; Emilie Varey; David Moreno Ramirez; Reinhard Dummer; Joanna Mangana; Axel Hauschild; Friederike Egberts; Ketty Peris; Laura Del Regno; Ana-Maria Forsea; Sabina A Zurac; Ricardo Vieira; Ana Brinca; Iris Zalaudek; Teresa Deinlein; Eleni Linos; Evangelos Evangelou; John F Thompson; Richard A Scolyer; Claus Garbe; Alexander J Stratigos
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

4.  KLF10 upregulates ACSM3 via the PI3K/Akt signaling pathway to inhibit the malignant progression of melanoma.

Authors:  Zhirong Zhao; Yuanchang Zhan; Li Jing; Huali Zhai
Journal:  Oncol Lett       Date:  2022-04-13       Impact factor: 2.967

Review 5.  Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Authors:  Hildur Helgadottir; Iara Rocha Trocoli Drakensjö; Ada Girnita
Journal:  Front Oncol       Date:  2018-06-12       Impact factor: 6.244

6.  Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.

Authors:  Yasuhiro Fujisawa; Shusuke Yoshikawa; Akane Minagawa; Tatsuya Takenouchi; Kenji Yokota; Hiroshi Uchi; Naoki Noma; Yasuhiro Nakamura; Jun Asai; Junji Kato; Susumu Fujiwara; Satoshi Fukushima; Jiro Uehara; Toshihiko Hoashi; Tatsuya Kaji; Taku Fujimura; Kenjiro Namikawa; Manabu Yoshioka; Naoki Murao; Dai Ogata; Kanako Matsuyama; Naohito Hatta; Yoshitsugu Shibayama; Toshiharu Fujiyama; Masashi Ishikawa; Daisuke Yamada; Akiko Kishi; Yoshiyuki Nakamura; Takatoshi Shimiauchi; Kazuyasu Fujii; Manabu Fujimoto; Hironobu Ihn; Norito Katoh
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

Review 7.  Targeted Therapy and Immunotherapy for Melanoma in Japan.

Authors:  Kenjiro Namikawa; Naoya Yamazaki
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

8.  The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma.

Authors:  Xiaoting Wei; Di Wu; Hang Li; Rui Zhang; Yu Chen; Hong Yao; Zhihong Chi; Xinan Sheng; Chuanliang Cui; Xue Bai; Zhonghui Qi; Ke Li; Shijie Lan; Lizhu Chen; Rui Guo; Xinyu Yao; Lili Mao; Bin Lian; Yan Kong; Jie Dai; Bixia Tang; Xieqiao Yan; Xuan Wang; Siming Li; Li Zhou; Charles M Balch; Lu Si; Jun Guo
Journal:  Ann Surg Oncol       Date:  2020-04-06       Impact factor: 5.344

Review 9.  Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.

Authors:  Patricia Basurto-Lozada; Christian Molina-Aguilar; Carolina Castaneda-Garcia; Martha Estefania Vázquez-Cruz; Omar Isaac Garcia-Salinas; Alethia Álvarez-Cano; Héctor Martínez-Said; Rodrigo Roldán-Marín; David J Adams; Patricia A Possik; Carla Daniela Robles-Espinoza
Journal:  Pigment Cell Melanoma Res       Date:  2020-06-17       Impact factor: 4.693

10.  Acral lentiginous melanoma-Population, treatment, and survival using the NCDB from 2004 to 2015.

Authors:  Shelly X Bian; Lindsay Hwang; Jennifer Hwang; Omar Ragab; Gino K In; David Peng; Eugene Lin
Journal:  Pigment Cell Melanoma Res       Date:  2021-08-02       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.